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TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer
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S_ary In ovarian cancer patients a 6 kDa polypeptide, the tumour-associated trypsin inhibitor (TATI),
can occur at elevated concentrations in both unrne and serum. In this study pretreatment serum levels ofTATI
(cut-off point 21 ngml-') and CA 125 (cut-off points 35Uml-' and 65Uml-') were determined in 152
patients with epithelial ovarian cancer (115 primary and 37 recurrent) and in 267 women with benign pelvic
diseases. The data obtained were correlated with the tumour stage, histological type and tumour grade.
Overall, TATI showed a sensitivity of 64% and a specificity of 75%. The sensitivity and specificity of CA
125 > 35 U ml-' were both 80%. Corresponding values for CA 125 > 65 U ml-' were 70% and 87%. The
combination of the two markers increased the sensitivity to 91% (CA 125> 35 U ml-') and 86% (CA
125 > 65 U ml-'), while the specificity dropped to 61% and 68% respectively. TATI was clearly superior in
mucinous carcinomas of the ovary, the rate of true-positive findings in these neoplasms was 67% vs 42% for
CA 125 > 35 U ml-' and 33% for CA 125 > 65 U ml-'. Unlike CA 125, TATI correlated well with tumour
grade. The combination of the two markers had a higher negative predictive value, i.e. 93% (CA 125 > 35 U
ml-1) and 90% (CA 125 > 65 U ml-') respectively. It is concluded that, while TATI cannot replace CA 125 in
the diagnosis of malignant epitheial carcinomas of the ovaries, it is a valuable additional marker in cases of
mucinous carcinomas and in combination with CA 125.
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With a sensitivity of more than 80%, the tumour marker CA
125 plays a major role in the detection and follow-up of
ovarian cancer. In patients with malignant ovarian neoplasms
another potential marker can, however, occur at elevated
concentrations in both urine and serum: a 6 kDa polypep-
tide, the tumour-associated trypsin inhibitor TATI. Its struc-
ture is identical to that of PSTI, the pancreatic secretory
trypsin inhibitor, which protects the pancreas from auto-
digestion (Stenman et al., 1982; Huhtala et al., 1982, 1983).
As TATI suppresses both the tumour-associated isoenzymes
TAT-1 and TAT-2 which may promote tumour invasion by
activating prourokinase, it inhibits tissue destruction by tryp-
sin (Koivunen et al., 1989) and is thus an indicator of the
proteolytic activity of the tumour.
While high TATI levels are present in the cyst fluid ofboth
benign and malignant mucinous ovarian cysts, concentrations
in serous fluids are elevated only in the presence of car-
cinoma. However, concentrations found in the cyst fluid do
not correlate with the serum levels (Hahila et al., 1987).
Elevated TATI levels have also been shown to be present in
90% of all pancreatic carcinomas and in 60-70% of gastro-
intestinal carcinomas (Haglund et al., 1986; Tomita et al.,
1990). In malignant ovarian neoplasms, TATI mainly
appears to be useful for detecting mucinous carcinomas
(Mogensen et al., 1990a, Torre et al., 1991).
The purpose of this study was to determine whether TATI
provides information other than that provided by CA 125
when used as a marker for epithelial carcinoma of the
ovary.
Materials and metod
Between May 1988 and June 1993 serum levels of CA 125
and TATI were determined before laparotomy in 419 con-
secutive patients with epithelial carcinoma of the ovary
(n = 152) or benign pelvic disease (n = 267). The patients
were between 23 and 87 years of age (mean age 62.4 years).
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All neoplasms were evaluated histologically. Staging was
based on the FIGO classification from 1985. For histological
typing the WHO recommendations were used (Serov et al.,
1973) and grading was performed according to Day et al.
(1975) (Table I).
As surgery is known to induce elevated serum levels, sam-
ples obtained within the first 4 weeks post-operatively were
not considered (Matsuda et al., 1985).
A cut-off point of 21 ngml-l was defined for TATI. This
was computed from the data obtained in 149 healthy women,
which showed a distribution skewed to the right with a
median of 12.9 ng ml-' and a mean of 13.8 ng ml-'. The 5th
and the 95th percentiles were 7.6 and 21.1 ng ml-' respec-
tively.
The 95th percentile of CA 125 in the 149 healthy women
was 35.9Uml-' with a mean of 15.3 Uml-' and a median
of 12.1 Uml-I. In accordance with the recommendation of
the supplier, 35 U ml-' and 65 U ml1' were taken as cut-off
points for CA 125 (Klug et al., 1984).
The CA 125 assay was a radioimmunoassay obtained from
Centocor (Malvern, PA, USA) and the TATI radioimmuno-
assay was obtained from Orion Diagnostica (Espoo, Fin-
land). All assays were performed in duplicate.
Serum samples were collected before operation and treat-
ment, divided into aliquots and stored at -20-C until tested.
The study was conducted 'blind', i.e. sera were coded before
being sent to the laboratory and the diagnosis revealed only
after the sera were tested.
Data analysis
TATI and CA 125 data were correlated with tumour stage,
histological type and tumour grade. The proportion of
patients with levels above designated cut-off points for each
assay were determined for the disease classifications. The
sensitivity, specificity and positive and negative predictive
value of each test for discriminating between ovarian cancer
and benign gynaecological disease were assessed and receiver
operating characteristic (ROC) curves were constructed for
each assay. In addition, ROC curves were constructed over a
range of CA 125 levels combined with a constant positive
level for TATI of 21 ngml-' and a range of TATI levels
combined with a constant level for CA 125 of 35 U ml-'. For
statistical analysis, the Kruskal-Wallis test was used.TATI . inuwu-i cw
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Table I Number (%) of patients with epithelial ovarian cancer (tumour stage, histology, tumour grade) with increased
marker levels
Number of TATI>21 or TATI>21 or
patients (n) TATI> 21 CA 125>35 CA 125>65 CA 125>35 CA 125>65
Tumour stage
I 35 14 (40) 17 (49) 12 (34) 25 (71) 20 (57)
II 10 7 (70) 9 (90) 8 (80) 10 (100) 10 (100)
III 58 43 (74) 55 (95) 51 (90) 58 (100) 57 (98)
IV 12 11 (92) 9 (75) 8 (67) 12 (100) 11 (92)
Recurrent 37 22 (59) 32 (86) 28 (76) 34 (92) 33 (89)
Histology
Serous 117 73 (62) 98 (84) 85 (73) 106 (91) 100 (85)
Mucinous 12 8 (67) 5 (42) 4 (33) 9 (75) 8 (67)
Undifferentiated 13 9 (69) 10 (77) 9 (69) 13 (100) 12 (92)
Endometrioid 12 7 (58) 9 (75) 9 (75) 11 (92) 11 (92)
Total 152 97 (64) 122 (80) 107 (70) 139 (91) 131 (86)
Tumour grade
1 32 11 (34) 17 (53) 13 (41) 23 (72) 19 (59)
2 49 28 (57) 45 (92) 40 (82) 46 (94) 44 (90)
3 54 43 (80) 48 (89) 45 (83) 54 (100) 53 (98)
Total 135 82 (61) 110 (81) 98 (73) 123 (91) 116 (86)
Table H Pretherapeutic TATI serum levels (mean, median, standard
deviation, range and 95th percentile) in 152 patints with stage I, H, III, IV and
recurrent ovarian carcinomas
Standard Range
Stage n Mean Median deviation (mi-max) 95% P
I 35 28.1 18.7 24.8 123.0 101.7
(6.7-129.7)
II 10 196.7 37.5 404.1 1309.6
(8.0-1317.7)
III 58 76.8 34.4 92.4 392.5
(7.8-400.3) 293.8
IV 12 73.7 50.8 84.1 312.5
(14.5-327.0) 1038.9
Recurrent 37 127.8 31.2 325.2 1793.7
(6.3-1800)
Reslts
Of the 152 women, 115 presented with primary epithelial
carcinoma of the ovary, while 37 had recurrent neoplasms. In
patients with stage I disease, neither TATI nor CA 125 > 35
U ml- or > 65 U ml-l was found to be useful. The sensi-
tivity of less than 50%i. for each of the markers alone was,
however, improved by combining them: levels above the
cut-off points were obtaineA in 71% of cases with TATI and
CA 125 > 35 U ml-' and in 57% of cases with TATI and
CA 125>65Uml-'. In all other stages the positivity rate
for TATI varied between 70% and 92%. While CA 125 was
clearly more useful in patients with stage HI disease, i.e. the
most common stage at the time of diagnosis, TATI was
found to have a higher sensitivity in patients with stage IV
disease. Combined with CA 125 > 35 Uml'1, TATI detected
all stage II-IV carcinomas. Combination with CA
125 > 65 U ml-' was found to give a detection rate of 100%
in stage II, of 98% in stage III and 92% in stage IV. The
sensitivity of TATI for detecting recurrent tumours was 59%
vs 86% for CA 125 > 35 U ml-' and 76% for CA 125 > 65
U ml'-. In combination the two markers detected 92%
(>35 U ml-l) and 89% (>65 U ml-l) of recurrent tumours
(Table I).
TATI failed to show any correlation with the tumour
stage. In fact, serum levels in patients with stage II, III and
IV disease and in those with recurrent tumours did not differ
significantly. Only patients with stage I disease were found to
have clearly lower TATI levels (Table II). One explanation
for the high levels of TATI in stage H could be a value of
1317.7 ng ml-' in one patient. Excluding this sample, the
mean value decreases to 72.2 ng ml-' and the median value
to 35.7 ngml-', with a standard deviation of 96 and a max-
imum of 300.3 ng ml'.
Analysis of the data by histological type showed tumour-
associated trypsin inhibitor to be more efficient in mucinous
tumours than CA 125. Its sensitivity in this histological type
was 67% vs 42% for CA 125 > 35 Uml-' and 33% for CA
125>65 U ml-'. In serous carcinomas of the ovaries only
62% of the TATI levels were above the cut-off point com-
pared with 84% for CA 125 > 35 Uml-' and 73% for CA
125 > 65 U ml-' (Table I). In mucinous tumours the com-
bination of the two markers did not produce any substantial
benefits. But in all other carcinomas their combined use
improved the sensitivity. Serum levels did not differ
significantly between different histological types.
TATI levels correlated well with tumour grade: they were
low in highly differentiated tumours, but clearly higher in
poorly differentiated carcinomas (P<0.0001) (Table II), and
their sensitivity increased with decreasing differentiation.
Serum levels above the cut-off point of 21 ngml-1 were
present in 34% of grade 1 tumours, in 57% of grade 2
tumours and in 80% of grade 3 tumours. In combination
with CA 125, TATI correctly diagnosed poorly differentiated
carcinomas in 100% (CA 125 cut-off 35 Uml-') and in 98%
(cut-off 65 U ml-') of cases, (Table I).
In the 267 women with benign pelvic disease the outcome
of TATI assays was false positive in 25% of cases vs 22%
and 13% for CA 125 > 35 U ml-' and CA 125 > 65 U ml-'
respectively. Inflammatory conditions of the internal genital
organs accounted most often for false-positive test outcomes
(50% of the false-positive TATI findings vs 39% for both CA
125 > 35 U ml-' and CA 125 > 65 Uml-l). These were fol-
lowed by endometriosis (29% vs 33% and 13% respectively).TAI in ouwim caner
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Table ]II Pretherapeutic TATI serum keels (mean, median, standard
deviation, range and 95th percentile) in 135 patients with ovarian cancer in
correlation with the tumour grade
Standard Range
Stage n Mean Median deviation (mi-max) 95% P
1 32 24.7 18.4 22.5 123.4 79.1
(6.3-129.7)
2 49 61.2 24.9 78.0 290.3 258.5
(10.0-300.3)
3 54 132.8 46.2 276.3 1792.2 538.8
(7.8-1800)
Tabek IV TATI and CA 125 levels in benign pelvic disease
Number of TATI>21 or TATI>21 or
patients (n) TATI>21 CA 125>35 CA 125>65 CA 125>35 CA 125>65
Ovarian cysts 125 23 (18) 13 (10) 5 (4) 33 (26) 27 (2)
Uterine fibroids 34 5 (15) 5 (15) 3 (9) 8 (23) 7 (21)
Hyperstimulation 11 5 (45) 7 (64) 6 (54) 9 (82) 9 (82)
Endometriosis 69 20 (29) 23 (33) 9 (13) 38 (55) 25 (36)
Inflammatory 28 14 (50) 11 (39) 11 (39) 17 (61) 17 (61)
Adnexal tumours
Total 267 67 (26) 59 (23) 34 (13) 105 (39) 85 (32)
Table V Overall sensitivity, ecificity, positive and negative predictive value in 152 patients
with epithelial ovarian cancer
Positive Negative
Sensitiviy Speccity predictive value predictive vahle
TAT] 64 75 59 78
CA 125>35Uml-l 80 80 67 87
CA 125>65 U ml-' 70 87 76 84
TATI/CA 125>35UmV-1 91 61 57 93
TATI/CA 125>65Uml'- 86 68 61 90
With the combined use of the two markers the rate of
false-positive diagnoses was as high as 50% in patients with
endometriosis. Ovarian hyperstimulation of patients seeking
pregnancy was another common cause of increased tumour
marker levels (45% for TATI vs 64% and 55% for CA 125)
(Table MV).
These figures add up to an overall sensitivity of 64% and
an overall specificity of 75% for TATI. Depending on the
cut-off level chosen, CA 125 showed sensitivities of 80% and
70% and specifcities of 80% and 87%. In combination, the
two markers showed a sensitivity of 91% and 86%. This
improvement was, however, bought at the expense of a lower
specificity (61% and 68%). But the combination showed an
outstanding rate of true-negative findings (93% and 90%
respectively) (Table V).
ROC curves were constructed for each assay and a com-
bination of the two markers (Figure 1). These curves show
that CA 125 has greater sensitivity than TATI over all levels
of specificity. Because of the independence of expression of
TATI and CA 125, improved discrimination between benign
and malignant tumours can be achieved by using both tests
in combination. The ROC curves with a constant positive
level for TATI of 21 ngml-' or a constant level for CA 125
of 35 U nil-' show an increase of sensitivity with a specificity
of no more than 76% (constant level for TATU) or 79%
(constant level for CA 125) respectively.
Disaie-o
In this study the potential of TATI to predict the malignancy
of pelvic tumours was evaluated and compared with that of
CA 125. Because of its sensitivity of 70-80% and its
specificity of 80-87%, CA 125 continues to be the most
important marker in the preoperative diagnosis of pelvic
tumours and in the detection of recurrent tumour growth.
However, our data do not match the impressive results of











Flgwe 1 Receiver operating characteristic curves showing the
relationship between sentvity and specificty in the dicina-
tion between benign adnexal masses and epitheli ovarian car-
cinoma for TATI (0), CA 125 (A), a combination ofTATI with
a constant positive kevel for CA 125 (>35 Uml-') (*) and a
combination of CA 125 with a constant positive level for TATI
(>21ngml-') (+).
other studies (O'Connell et al., 1987) with a reported sen-
sitivity and negative predictive value of 100%. Particularly in
stage I disease, we found the sensitivity of CA 125 to be
quite poor (49% and 34% depending on the cut-off level
chosen). Combined, the two markers detected 100% of all
stage III malignancies. Of the recurrent tumours, 86% and
76% were detected by CA 125, while the detection rate of
n 1rv T I- ,uTATI in o,ian cancer
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TATI was only just under 70%. Except in stage IV disease,
CA 125 was clearly superior to tumour-associated trypsin
inhibitor. However, in patients with a negative CA 125 test
outcome. TATI provided additional staging information at
all tumour stages. These results confirm the results of a
previously published study (Mogensen et al., 1990b).
Like Mogensen et al. (1990a) and Torre et al. (1991), we
found TATI to offer substantial benefits compared with CA
125 in the diagnosis of mucinous carcinomas of the ovaries.
In these cases its sensitivity was 67% vs 42% and 33% for
CA 125. Although slightly lower, the true positivity rate of
TATI (69%) more or less matched that of CA 125 (69% and
77%) in undifferentiated malignant neoplasms. But in serous
carcinomas CA 125 showed a much better sensitivity, which
was better still when the two markers were combined (91%).
In mucinous carcinomas, by contrast, the combined use of
the markers left the sensitivity unchanged.
In contrast to the results obtained by Torre et al. (1989)
based on a small number of cases, our data showed a close
correlation with the tumour grade both for the rate of true-
positive findings and the TATI serum levels. Combined, the
two markers correctly diagnosed 100% and 98% of the
poorly differentiated ovarian neoplasms (depending on the
cut-off level chosen for CA 125). Of the intermediate-grade
ovarian carcinomas, no less than 94% and 90% were still
correctly diagnosed by the combination of CA 125 and
TATI.
That TATI is an acute-phase protein was shown in 1989
by Paavonen et al. in a comparative study with CRP. In
contrast to the findings of Gaducci et at. (1991), in our study
the rate of false-positive findings in patients with benign
abnormalities of the pelvis, particularly in those with
inflammatory conditions (50%), ovarian hyperstimulation to
facilitate conception (45%) and in endometriosis (29%), was
exceedingly high. Like CA 125, TATI may thus have a place
in monitoring patients with endometnrosis. However, in con-
trast to reported data (Gadducci et al., 1992), we found the
specificity of TATI to be no better than 75%, while that of
CA 125 was substantially improved by increasing the cut-off
level from 35 U ml-' to 65 Umrl-l (78% vs 87%).
In conclusion, CA 125 continues to be the tumour marker
of first choice for evaluation of pelvic masses. But the
tumour-associated trypsin inhibitor (TATI) provides a valu-
able supplementary test for mucinous carcinomas of the
ovaries and for ovarian neoplasms with a negative CA 125
test outcome. The extremely high negative predictive value
obtained with TATI in combination with CA 125 (93% and
90%) is, no doubt, of particular interest. If both TATI and
CA 125 levels are within normal, the occurrence of epithelial
carcinoma of the ovaries is not very likely.
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